Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Aug;78(4):454–459. doi: 10.1038/bjc.1998.514

Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma.

T Fukuura 1, C Miki 1, T Inoue 1, K Matsumoto 1, H Suzuki 1
PMCID: PMC2063100  PMID: 9716026

Abstract

To evaluate the clinical significance of serum levels of hepatocyte growth factor (HGF) in colorectal cancer patients, we measured the venous and portal concentrations of HGF in 60 patients. The tissue concentrations in the tumour and adjacent normal mucosa were also determined. The serum HGF concentration for the peripheral venous blood of the patients was significantly higher than that in normal controls. The content of HGF in cancer tissue was also significantly higher than that in normal mucosa, and it was correlated with the serum HGF concentration for the peripheral venous blood. The serum concentration of HGF reflected pathological features, including tumour size and lymph node or liver metastasis, and it showed an association with various preoperative nutritional parameters and the preoperative haemoglobin level. The serum HGF concentration was also correlated with the serum concentrations of immunosuppressive acidic protein and interleukin-6, indices of the host's immunological condition. Serum HGF seems to be a useful index of the disease status of patients with colorectal carcinoma.

Full text

PDF
454

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beviglia L., Matsumoto K., Lin C. S., Ziober B. L., Kramer R. H. Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer. 1997 Jun 20;74(3):301–309. doi: 10.1002/(sici)1097-0215(19970620)74:3<301::aid-ijc12>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  2. Blood C. H., Zetter B. R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta. 1990 Jun 1;1032(1):89–118. doi: 10.1016/0304-419x(90)90014-r. [DOI] [PubMed] [Google Scholar]
  3. Braga M., Baccari P., Scaccabarozzi S., Fiacco E., Radaelli G., Gallus G., DiPalo S., DiCarlo V., Cristallo M. Prognostic role of preoperative nutritional and immunological assessment in the surgical patient. JPEN J Parenter Enteral Nutr. 1988 Mar-Apr;12(2):138–142. doi: 10.1177/0148607188012002138. [DOI] [PubMed] [Google Scholar]
  4. Bussolino F., Di Renzo M. F., Ziche M., Bocchietto E., Olivero M., Naldini L., Gaudino G., Tamagnone L., Coffer A., Comoglio P. M. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992 Nov;119(3):629–641. doi: 10.1083/jcb.119.3.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Castell J. V., Gómez-Lechón M. J., David M., Fabra R., Trullenque R., Heinrich P. C. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990 Nov;12(5):1179–1186. doi: 10.1002/hep.1840120517. [DOI] [PubMed] [Google Scholar]
  6. Dannhauser A., Van Zyl J. M., Nel C. J. Preoperative nutritional status and prognostic nutritional index in patients with benign disease undergoing abdominal operations--Part II. J Am Coll Nutr. 1995 Feb;14(1):91–98. doi: 10.1080/07315724.1995.10718478. [DOI] [PubMed] [Google Scholar]
  7. Gambardella A., Tortoriello R., Tagliamonte M. R., Paolisso G., Varricchio M. Metabolic changes in elderly cancer patients after glucose ingestion. The role of tumor necrosis factor-alpha. Cancer. 1997 Jan 1;79(1):177–184. [PubMed] [Google Scholar]
  8. Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7251–7255. doi: 10.1073/pnas.84.20.7251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gherardi E., Stoker M. Hepatocytes and scatter factor. Nature. 1990 Jul 19;346(6281):228–228. doi: 10.1038/346228b0. [DOI] [PubMed] [Google Scholar]
  10. Grant D. S., Kleinman H. K., Goldberg I. D., Bhargava M. M., Nickoloff B. J., Kinsella J. L., Polverini P., Rosen E. M. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1937–1941. doi: 10.1073/pnas.90.5.1937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Göransson J., Jonsson S., Lasson A. Pre-operative plasma levels of C-reactive protein, albumin and various plasma protease inhibitors for the pre-operative assessment of operability and recurrence in cancer surgery. Eur J Surg Oncol. 1996 Dec;22(6):607–617. doi: 10.1016/s0748-7983(96)92398-7. [DOI] [PubMed] [Google Scholar]
  12. Hirota M., Egami H., Corra S., Fujii H., Chaney W. G., Rizzino A., Pour P. M. Production of scatter factor-like activity by a nitrosamine-induced pancreatic cancer cell line. Carcinogenesis. 1993 Feb;14(2):259–264. doi: 10.1093/carcin/14.2.259. [DOI] [PubMed] [Google Scholar]
  13. Jiang W. G., Hallett M. B., Puntis M. C. Hepatocyte growth factor/scatter factor, liver regeneration and cancer metastasis. Br J Surg. 1993 Nov;80(11):1368–1373. doi: 10.1002/bjs.1800801104. [DOI] [PubMed] [Google Scholar]
  14. Jin L., Fuchs A., Schnitt S. J., Yao Y., Joseph A., Lamszus K., Park M., Goldberg I. D., Rosen E. M. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer. 1997 Feb 15;79(4):749–760. doi: 10.1002/(sici)1097-0142(19970215)79:4<749::aid-cncr12>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  15. Kaneko A., Hayashi N., Tanaka Y., Ito T., Kasahara A., Kubo M., Mukuda T., Fusamoto H., Kamada T. Changes in serum human hepatocyte growth factor levels after transcatheter arterial embolization and partial hepatectomy. Am J Gastroenterol. 1992 Aug;87(8):1014–1017. [PubMed] [Google Scholar]
  16. Keller U. Pathophysiology of cancer cachexia. Support Care Cancer. 1993 Nov;1(6):290–294. doi: 10.1007/BF00364965. [DOI] [PubMed] [Google Scholar]
  17. Kiehne K., Herzig K. H., Fölsch U. R. c-met expression in pancreatic cancer and effects of hepatocyte growth factor on pancreatic cancer cell growth. Pancreas. 1997 Jul;15(1):35–40. doi: 10.1097/00006676-199707000-00005. [DOI] [PubMed] [Google Scholar]
  18. Liu C., Park M., Tsao M. S. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene. 1992 Jan;7(1):181–185. [PubMed] [Google Scholar]
  19. Maas-Szabowski N., Fusenig N. E. Interleukin-1-induced growth factor expression in postmitotic and resting fibroblasts. J Invest Dermatol. 1996 Dec;107(6):849–855. doi: 10.1111/1523-1747.ep12331158. [DOI] [PubMed] [Google Scholar]
  20. Matsumoto K., Masuda T., Terashima H., Matsumoto K., Iriyama K., Suzuki H. Correlation between serum immunosuppressive substance and clinico-pathological findings in patients with gastric carcinoma. Jpn J Surg. 1988 May;18(3):369–372. doi: 10.1007/BF02471458. [DOI] [PubMed] [Google Scholar]
  21. Matsumoto K., Tajima H., Hamanoue M., Kohno S., Kinoshita T., Nakamura T. Identification and characterization of "injurin," an inducer of expression of the gene for hepatocyte growth factor. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3800–3804. doi: 10.1073/pnas.89.9.3800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mayer B., Johnson J. P., Leitl F., Jauch K. W., Heiss M. M., Schildberg F. W., Birchmeier W., Funke I. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. 1993 Apr 1;53(7):1690–1695. [PubMed] [Google Scholar]
  23. Miyazaki M., Bai L., Taga H., Hirai H., Sato J., Namba M. Expression of liver-specific functions and secretion of a hepatocyte growth factor by a newly established rat hepatoma cell line growing in a chemically-defined serum-free medium. Res Exp Med (Berl) 1991;191(5):297–307. doi: 10.1007/BF02576686. [DOI] [PubMed] [Google Scholar]
  24. Naka T., Iwamoto Y., Shinohara N., Ushijima M., Chuman H., Tsuneyoshi M. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Pathol. 1997 Aug;10(8):832–838. [PubMed] [Google Scholar]
  25. Nakamura T., Matsumoto K., Kiritoshi A., Tano Y., Nakamura T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res. 1997 Aug 1;57(15):3305–3313. [PubMed] [Google Scholar]
  26. Nishi M., Hiramatsu Y., Hioki K., Kojima Y., Sanada T., Yamanaka H., Yamamoto M. Risk factors in relation to postoperative complications in patients undergoing esophagectomy or gastrectomy for cancer. Ann Surg. 1988 Feb;207(2):148–154. doi: 10.1097/00000658-198802000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Noji S., Tashiro K., Koyama E., Nohno T., Ohyama K., Taniguchi S., Nakamura T. Expression of hepatocyte growth factor gene in endothelial and Kupffer cells of damaged rat livers, as revealed by in situ hybridization. Biochem Biophys Res Commun. 1990 Nov 30;173(1):42–47. doi: 10.1016/s0006-291x(05)81018-6. [DOI] [PubMed] [Google Scholar]
  28. Ohira H., Miyata M., Kuroda M., Takagi T., Tojo J., Ochiai H., Kokubun M., Nishimaki T., Kasukawa R., Obara K. Interleukin-6 induces proliferation of rat hepatocytes in vivo. J Hepatol. 1996 Dec;25(6):941–947. doi: 10.1016/s0168-8278(96)80300-x. [DOI] [PubMed] [Google Scholar]
  29. Oka M., Mitsunaga H., Hazama S., Yoshino S., Suzuki T. Natural killer activity and serum immunosuppressive acidic protein levels in esophageal and gastric cancers. Surg Today. 1993;23(8):669–674. doi: 10.1007/BF00311703. [DOI] [PubMed] [Google Scholar]
  30. Oka M., Yamamoto K., Takahashi M., Hakozaki M., Abe T., Iizuka N., Hazama S., Hirazawa K., Hayashi H., Tangoku A. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res. 1996 Jun 15;56(12):2776–2780. [PubMed] [Google Scholar]
  31. Pisters L. L., el-Naggar A. K., Luo W., Malpica A., Lin S. H. C-met proto-oncogene expression in benign and malignant human renal tissues. J Urol. 1997 Sep;158(3 Pt 1):724–728. doi: 10.1097/00005392-199709000-00009. [DOI] [PubMed] [Google Scholar]
  32. Ramadori G., Neubauer K., Odenthal M., Nakamura T., Knittel T., Schwögler S., Meyer zum Büschenfelde K. H. The gene of hepatocyte growth factor is expressed in fat-storing cells of rat liver and is downregulated during cell growth and by transforming growth factor-beta. Biochem Biophys Res Commun. 1992 Mar 16;183(2):739–742. doi: 10.1016/0006-291x(92)90545-v. [DOI] [PubMed] [Google Scholar]
  33. Revoltella R. P., Borney F., Dal Canto B., D'Urso C. M. Apoptosis of serum-free C2.8 mouse embryo hepatocytic cells caused by hepatocyte growth factor deprivation. Cytotechnology. 1993;13(1):13–19. doi: 10.1007/BF00749971. [DOI] [PubMed] [Google Scholar]
  34. Rosen E. M., Meromsky L., Setter E., Vinter D. W., Goldberg I. D. Smooth muscle-derived factor stimulates mobility of human tumor cells. Invasion Metastasis. 1990;10(1):49–64. [PubMed] [Google Scholar]
  35. Rygaard K., Nakamura T., Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer. 1993 Jan;67(1):37–46. doi: 10.1038/bjc.1993.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Schiffmann E. Motility as a principal requirement for metastasis. Cancer Invest. 1990;8(6):673–674. doi: 10.3109/07357909009018943. [DOI] [PubMed] [Google Scholar]
  37. Schirmacher P., Geerts A., Pietrangelo A., Dienes H. P., Rogler C. E. Hepatocyte growth factor/hepatopoietin A is expressed in fat-storing cells from rat liver but not myofibroblast-like cells derived from fat-storing cells. Hepatology. 1992 Jan;15(1):5–11. doi: 10.1002/hep.1840150103. [DOI] [PubMed] [Google Scholar]
  38. Shibata Y., Tamura K., Ishida N. In vivo analysis of the suppressive effects of immunosuppressive acidic protein, a type of alpha 1-acid glycoprotein, in connection with its high level in tumor-bearing mice. Cancer Res. 1983 Jun;43(6):2889–2896. [PubMed] [Google Scholar]
  39. Shima N., Nagao M., Ogaki F., Tsuda E., Murakami A., Higashio K. Tumor cytotoxic factor/hepatocyte growth factor from human fibroblasts: cloning of its cDNA, purification and characterization of recombinant protein. Biochem Biophys Res Commun. 1991 Oct 31;180(2):1151–1158. doi: 10.1016/s0006-291x(05)81187-8. [DOI] [PubMed] [Google Scholar]
  40. Souba W. W. Cytokine control of nutrition and metabolism in critical illness. Curr Probl Surg. 1994 Jul;31(7):577–643. doi: 10.1016/0011-3840(94)90047-7. [DOI] [PubMed] [Google Scholar]
  41. Stoker M., Gherardi E., Perryman M., Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987 May 21;327(6119):239–242. doi: 10.1038/327239a0. [DOI] [PubMed] [Google Scholar]
  42. Strassmann G., Jacob C. O., Evans R., Beall D., Fong M. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol. 1992 Jun 1;148(11):3674–3678. [PubMed] [Google Scholar]
  43. Sugiyama A., Arakaki R., Ohnishi T., Arakaki N., Daikuhara Y., Takada H. Lipoteichoic acid and interleukin 1 stimulate synergistically production of hepatocyte growth factor (scatter factor) in human gingival fibroblasts in culture. Infect Immun. 1996 Apr;64(4):1426–1431. doi: 10.1128/iai.64.4.1426-1431.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Tajima H., Matsumoto K., Nakamura T. Regulation of cell growth and motility by hepatocyte growth factor and receptor expression in various cell species. Exp Cell Res. 1992 Oct;202(2):423–431. doi: 10.1016/0014-4827(92)90095-p. [DOI] [PubMed] [Google Scholar]
  45. Takada N., Yano Y., Matsuda T., Otani S., Osugi H., Higashino M., Kinoshita H., Fukushima S. Expression of immunoreactive human hepatocyte growth factor in human esophageal squamous cell carcinomas. Cancer Lett. 1995 Nov 6;97(2):145–148. doi: 10.1016/0304-3835(95)03967-2. [DOI] [PubMed] [Google Scholar]
  46. Tamura K., Shibata Y., Matsuda Y., Ishida N. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res. 1981 Aug;41(8):3244–3252. [PubMed] [Google Scholar]
  47. Tamura M., Arakaki N., Tsubouchi H., Takada H., Daikuhara Y. Enhancement of human hepatocyte growth factor production by interleukin-1 alpha and -1 beta and tumor necrosis factor-alpha by fibroblasts in culture. J Biol Chem. 1993 Apr 15;268(11):8140–8145. [PubMed] [Google Scholar]
  48. Tanaka M., Miyazaki H., Takeda Y., Takeo S. Detection of serum cytokine levels in experimental cancer cachexia of colon 26 adenocarcinoma-bearing mice. Cancer Lett. 1993 Aug 16;72(1-2):65–70. doi: 10.1016/0304-3835(93)90012-x. [DOI] [PubMed] [Google Scholar]
  49. Taniguchi T., Kitamura M., Arai K., Iwasaki Y., Yamamoto Y., Igari A., Toi M. Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. Br J Cancer. 1997;75(5):673–677. doi: 10.1038/bjc.1997.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Taniguchi T., Toi M., Inada K., Imazawa T., Yamamoto Y., Tominaga T. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res. 1995 Sep;1(9):1031–1034. [PubMed] [Google Scholar]
  51. Tannapfel A., Wittekind C., Tahara E. Effect of hepatocyte growth factor (HGF)/scatter factor (SF) on cell adhesion in gastric cancer. Z Gastroenterol. 1994 Feb;32(2):91–93. [PubMed] [Google Scholar]
  52. Triantafillidis J. K., Papatheodorou K., Kogevinas M., Manoussakis K., Nicolakis D. Prognostic factors affecting the survival of operated patients with colorectal cancer: significance of delayed hypersensitivity skin reactions and nutritional status. Ital J Gastroenterol. 1995 Oct-Nov;27(8):419–424. [PubMed] [Google Scholar]
  53. Tsubouchi H., Niitani Y., Hirono S., Nakayama H., Gohda E., Arakaki N., Sakiyama O., Takahashi K., Kimoto M., Kawakami S. Levels of the human hepatocyte growth factor in serum of patients with various liver diseases determined by an enzyme-linked immunosorbent assay. Hepatology. 1991 Jan;13(1):1–5. [PubMed] [Google Scholar]
  54. Ueki T., Fujimoto J., Suzuki T., Yamamoto H., Okamoto E. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology. 1997 Apr;25(4):862–866. doi: 10.1002/hep.510250413. [DOI] [PubMed] [Google Scholar]
  55. Weidner K. M., Arakaki N., Hartmann G., Vandekerckhove J., Weingart S., Rieder H., Fonatsch C., Tsubouchi H., Hishida T., Daikuhara Y. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7001–7005. doi: 10.1073/pnas.88.16.7001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Weidner K. M., Behrens J., Vandekerckhove J., Birchmeier W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol. 1990 Nov;111(5 Pt 1):2097–2108. doi: 10.1083/jcb.111.5.2097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Weng J., Mohan R. R., Li Q., Wilson S. E. IL-1 upregulates keratinocyte growth factor and hepatocyte growth factor mRNA and protein production by cultured stromal fibroblast cells: interleukin-1 beta expression in the cornea. Cornea. 1997 Jul;16(4):465–471. [PubMed] [Google Scholar]
  58. Wolf H. K., Zarnegar R., Michalopoulos G. K. Localization of hepatocyte growth factor in human and rat tissues: an immunohistochemical study. Hepatology. 1991 Sep;14(3):488–494. [PubMed] [Google Scholar]
  59. Yamashita J., Ogawa M., Beppu T. Immunoreactive hepatocyte growth factor is present in tissue extracts from human breast cancer but not in conditioned medium of human breast cancer cell lines. Res Commun Chem Pathol Pharmacol. 1993 Nov;82(2):249–252. [PubMed] [Google Scholar]
  60. Yamashita J., Ogawa M., Yamashita S., Nomura K., Kuramoto M., Saishoji T., Shin S. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 1994 Apr 1;54(7):1630–1633. [PubMed] [Google Scholar]
  61. Yanagawa H., Sone S., Takahashi Y., Haku T., Yano S., Shinohara T., Ogura T. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer. 1995 May;71(5):1095–1098. doi: 10.1038/bjc.1995.212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Yanagita K., Nagaike M., Ishibashi H., Niho Y., Matsumoto K., Nakamura T. Lung may have an endocrine function producing hepatocyte growth factor in response to injury of distal organs. Biochem Biophys Res Commun. 1992 Jan 31;182(2):802–809. doi: 10.1016/0006-291x(92)91803-x. [DOI] [PubMed] [Google Scholar]
  63. Yoshinaga Y., Fujita S., Gotoh M., Nakamura T., Kikuchi M., Hirohashi S. Human lung cancer cell line producing hepatocyte growth factor/scatter factor. Jpn J Cancer Res. 1992 Dec;83(12):1257–1261. doi: 10.1111/j.1349-7006.1992.tb02755.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Zarnegar R., Muga S., Rahija R., Michalopoulos G. Tissue distribution of hepatopoietin-A: a heparin-binding polypeptide growth factor for hepatocytes. Proc Natl Acad Sci U S A. 1990 Feb;87(3):1252–1256. doi: 10.1073/pnas.87.3.1252. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES